132 related articles for article (PubMed ID: 32452048)
1. Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events.
Townsend M; Kamel H; Van Buren N; Wiersum-Osselton J; Rosa-Bray M; Gottschall J; Rajbhandary S
Transfusion; 2020 Jun; 60(6):1231-1242. PubMed ID: 32452048
[TBL] [Abstract][Full Text] [Related]
2. Knowledge assessment of a donor adverse reaction severity grading tool by the National Blood Donor Vigilance Programme of India.
Bisht A; Arora S; Patidar G; Marwaha N
Vox Sang; 2023 Sep; 118(9):721-729. PubMed ID: 37533234
[TBL] [Abstract][Full Text] [Related]
3. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study.
Cho JH; Rajbhandary S; van Buren NL; Fung MK; Al-Ghafry M; Fridey JL; Dy BA; Ziman A; Schreiber GB; Gammon RR; Reik R; Stubbs JR; van Buskirk CM; Kamel H; Townsend MJ; Zeller MP; Gottschall JL
Transfusion; 2021 Sep; 61(9):2668-2676. PubMed ID: 34227689
[TBL] [Abstract][Full Text] [Related]
4. International validation of harmonized definitions for complications of blood donations.
Land KJ; Townsend M; Goldman M; Whitaker BI; Perez GE; Wiersum-Osselton JC
Transfusion; 2018 Nov; 58(11):2589-2595. PubMed ID: 30294786
[TBL] [Abstract][Full Text] [Related]
5. Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study.
Wiersum-Osselton JC; Whitaker B; Grey S; Land K; Perez G; Rajbhandary S; Andrzejewski C; Bolton-Maggs P; Lucero H; Renaudier P; Robillard P; Santos M; Schipperus M
Lancet Haematol; 2019 Jul; 6(7):e350-e358. PubMed ID: 31080132
[TBL] [Abstract][Full Text] [Related]
6. AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance Module adverse events definitions protocol.
AuBuchon JP; Fung M; Whitaker B; Malasky J
Transfusion; 2014 Aug; 54(8):2077-83. PubMed ID: 24673261
[TBL] [Abstract][Full Text] [Related]
7. Development of standard definitions for surveillance of complications related to blood donation.
Goldman M; Land K; Robillard P; Wiersum-Osselton J
Vox Sang; 2016 Feb; 110(2):185-8. PubMed ID: 26361365
[TBL] [Abstract][Full Text] [Related]
8. The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results.
Politis C; Wiersum JC; Richardson C; Robillard P; Jorgensen J; Renaudier P; Faber JC; Wood EM
Vox Sang; 2016 Nov; 111(4):409-417. PubMed ID: 27658188
[TBL] [Abstract][Full Text] [Related]
9. How is national recipient hemovigilance conducted in the United States?
Chung KW; Harvey A; Basavaraju SV; Kuehnert MJ
Transfusion; 2015 Apr; 55(4):703-7. PubMed ID: 25565577
[TBL] [Abstract][Full Text] [Related]
10. Thirty years of hemovigilance - Achievements and future perspectives.
Vuk T; Politis C; Laspina S; Lozano M; Haddad A; de Angelis V; Garraud O;
Transfus Clin Biol; 2023 Feb; 30(1):166-172. PubMed ID: 36216308
[TBL] [Abstract][Full Text] [Related]
11. Proposing a Model for the National Hemovigilance Information System in Iran.
Asadi F; Ramezanghorbani N
J Med Life; 2020; 13(2):211-218. PubMed ID: 32742516
[TBL] [Abstract][Full Text] [Related]
12. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients.
Gu S; Menzer C; Hay JL; Pena C; Dusza S; Lacouture ME; Markova A
Support Care Cancer; 2023 May; 31(6):337. PubMed ID: 37183206
[TBL] [Abstract][Full Text] [Related]
13. [Delayed adverse reactions to blood donation: From haemovigilance data to specific studies].
Py JY; Durieux S; Barnoux M; Sapey T
Transfus Clin Biol; 2016 Nov; 23(4):233-239. PubMed ID: 27769684
[TBL] [Abstract][Full Text] [Related]
14. International haemovigilance: what have we learned and what do we need to do next?
Wood EM; Ang AL; Bisht A; Bolton-Maggs PH; Bokhorst AG; Flesland O; Land K; Wiersum-Osselton JC; Schipperus MR; Tiberghien P; Whitaker BI
Transfus Med; 2019 Aug; 29(4):221-230. PubMed ID: 30729612
[TBL] [Abstract][Full Text] [Related]
15. First donor haemovigilance system at a national level in China: Establishment and improvement.
Yang J; Fan D; Xie D; Guo X; Zhu W; He T; Huang X
Vox Sang; 2023 May; 118(5):357-366. PubMed ID: 36896482
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the National Healthcare Safety Network Hemovigilance Module for transfusion-related adverse reactions in the United States.
Edens C; Haass KA; Cumming M; Osinski A; O'Hearn L; Passanisi K; Eaton L; Visintainer P; Savinkina A; Kuehnert MJ; Basavaraju SV; Andrzejewski C
Transfusion; 2019 Feb; 59(2):524-533. PubMed ID: 30427540
[TBL] [Abstract][Full Text] [Related]
17. [Hemovigilance: State 2007-2013 Tunis].
Mahjoub S; Baccouche H; Raissi A; Ben Hamed L; Ben Romdhane N
Transfus Clin Biol; 2017 Feb; 24(1):15-22. PubMed ID: 27955922
[TBL] [Abstract][Full Text] [Related]
18. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
[TBL] [Abstract][Full Text] [Related]
19. Hemovigilance and the Notify Library.
Whitaker BI; Strong DM; Gandhi MJ; Petrisli E
Immunohematology; 2017 Dec; 33(4):159-164. PubMed ID: 29378148
[TBL] [Abstract][Full Text] [Related]
20. Transfusion-associated hazards: A revisit of their presentation.
Garraud O; Sut C; Haddad A; Tariket S; Aloui C; Laradi S; Hamzeh-Cognasse H; Bourlet T; Zeni F; Aubron C; Ozier Y; Laperche S; Peyrard T; Buffet P; Guyotat D; Tavernier E; Cognasse F; Pozzetto B; Andreu G
Transfus Clin Biol; 2018 May; 25(2):118-135. PubMed ID: 29625790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
